Revance Therapeutics, Inc.

Develops both topical and longer lasting injectable formulations of Botox

Transaction Summary

  • Completed a $110M IPO and $140M secondary in 2014 to fund clinical trials for both products
  • Moving forward on clinical trials in four separate indications for both topical and injectable
  • Released positive Phase II data on 6 month duration of RT002, the company's long lasting injectable